<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:media="http://search.yahoo.com/mrss/" version="2.0">
<channel>
<title><![CDATA[RSS for AstraZeneca]]></title>
<description><![CDATA[AstraZeneca news and video.  Watch AstraZeneca video clips and read news updates about AstraZeneca.]]></description>
<link><![CDATA[http://www.foxbusiness.com/search-results/]]></link>
<atom:link xmlns:atom="http://www.w3.org/2005/Atom" type="application/rss+xml" rel="self" href="http://www.foxbusiness.com/search-results/urss?pageid=217692"/>
<item>
<title><![CDATA[Analysis: Drugmakers face more scrutiny of discordant U.S. prices]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/10/analysis-drugmakers-face-more-scrutiny-discordant-us-prices/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/10/analysis-drugmakers-face-more-scrutiny-discordant-us-prices/</guid>
<pubDate><![CDATA[Fri, 10 May 2013 11:20:07 EDT]]></pubDate>
<description><![CDATA[The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Americans Spending Less on Medicines]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/08/us-spending-on-medicines-fell-for-first-time-in-2012/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/08/us-spending-on-medicines-fell-for-first-time-in-2012/</guid>
<pubDate><![CDATA[Wed, 08 May 2013 23:59:59 EDT]]></pubDate>
<description><![CDATA[Patent expirations on big-name drugs such as Lipitor and Plavix has resulted in modestly less spending on medicines in the United States for the first time in at least 55 years, according to a report released on Thursday.]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/medicine_pills_health_care.jpg</media:thumbnail>
</item>
<item>
<title><![CDATA[Bristol-Myers, AstraZeneca: Study Shows Metreleptin May Treat Pediatric Lipodystrophy]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/06/bristol-myers-astrazeneca-study-shows-metreleptin-may-treat-pediatric/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/06/bristol-myers-astrazeneca-study-shows-metreleptin-may-treat-pediatric/</guid>
<pubDate><![CDATA[Mon, 06 May 2013 07:43:12 EDT]]></pubDate>
<description><![CDATA[Bristol-Myers Squibb Co. (BMY) and AstraZeneca PLC (AZN) said a year-long study of metreleptin showed it reduced average blood sugar levels in pediatric patients with lipodystrophy.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[EUROPE MARKETS: Europe Stocks Rise As U.K. Avoids Recession]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/25/europe-markets-europe-stocks-rise-as-uk-avoids-recession/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/25/europe-markets-europe-stocks-rise-as-uk-avoids-recession/</guid>
<pubDate><![CDATA[Thu, 25 Apr 2013 12:05:36 EDT]]></pubDate>
<description><![CDATA[European stock markets posted their longest winning streak of the year on Thursday, after U.K.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[LONDON MARKETS: U.K. Stocks Rise As GDP Data Beat Views]]></title>
<link><![CDATA[http://www.foxbusiness.com/technology/2013/04/25/london-markets-uk-stocks-rise-as-gdp-data-beat-views/?]]></link>
<guid>http://www.foxbusiness.com/technology/2013/04/25/london-markets-uk-stocks-rise-as-gdp-data-beat-views/</guid>
<pubDate><![CDATA[Thu, 25 Apr 2013 12:03:47 EDT]]></pubDate>
<description><![CDATA[U.K.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[EUROPE MARKETS: Europe Stocks Erase Losses After U.K. GDP]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/25/europe-markets-europe-stocks-erase-losses-after-uk-gdp/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/25/europe-markets-europe-stocks-erase-losses-after-uk-gdp/</guid>
<pubDate><![CDATA[Thu, 25 Apr 2013 05:45:56 EDT]]></pubDate>
<description><![CDATA[European stock markets erased earlier losses on Thursday, after U.K.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Mixed Results for Drug Companies]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/25/mixed-results-for-drug-companies/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/25/mixed-results-for-drug-companies/</guid>
<pubDate><![CDATA[Thu, 25 Apr 2013 05:25:05 EDT]]></pubDate>
<description><![CDATA[AstraZeneca PLC (AZN.LN) said Thursday profit and sales fell for a fifth-consecutive quarter as the drug giant continues to suffer patent expiries that leave some of its blockbuster products open to competition from generic brands.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[LONDON MARKETS: U.K. Stocks Decline, Shrug Off GDP Data]]></title>
<link><![CDATA[http://www.foxbusiness.com/technology/2013/04/25/london-markets-uk-stocks-decline-shrug-off-gdp-data/?]]></link>
<guid>http://www.foxbusiness.com/technology/2013/04/25/london-markets-uk-stocks-decline-shrug-off-gdp-data/</guid>
<pubDate><![CDATA[Thu, 25 Apr 2013 05:23:54 EDT]]></pubDate>
<description><![CDATA[Weak earnings from some of the U.K.'s heavyweights weighed on London's benchmark stock index on Thursday, offsetting better-than-expected growth data for the country.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[AstraZeneca 1Q Pretax Profit Down 36%]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/25/astrazeneca-1q-pretax-profit-down-36/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/25/astrazeneca-1q-pretax-profit-down-36/</guid>
<pubDate><![CDATA[Thu, 25 Apr 2013 04:25:02 EDT]]></pubDate>
<description><![CDATA[AstraZeneca PLC (AZN.LN) Thursday reported pretax profit for first quarter of 1.3 billion dollars, down 36% from the same period last year and below analysts' expectations, as the loss of exclusivity for several brands affected performance in the first quarter as expected, and reiterated its guidance for the full year.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[AstraZeneca 1Q Pretax Profit -36% From 1Q12; Backs Fiscal Year Guidance]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/25/astrazeneca-1q-pretax-profit-36-from-1q12-backs-fiscal-year-guidance/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/25/astrazeneca-1q-pretax-profit-36-from-1q12-backs-fiscal-year-guidance/</guid>
<pubDate><![CDATA[Thu, 25 Apr 2013 02:38:31 EDT]]></pubDate>
<description><![CDATA[AstraZeneca PLC (AZN.LN) Thursday reported pretax profit for first quarter of 1.3 billion dollars, down 36% from the same period last year and below analysts' expectations, as the loss of exclusivity for several brands affected performance in the first quarter as expected, and reiterated its guidance for the full year.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[EARNINGS FORECAST TABLE: AstraZeneca 1Q 2013]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/23/earnings-forecast-table-astrazeneca-1q-2013/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/23/earnings-forecast-table-astrazeneca-1q-2013/</guid>
<pubDate><![CDATA[Tue, 23 Apr 2013 06:29:51 EDT]]></pubDate>
<description><![CDATA[The following is a summary of analysts' forecasts for AstraZeneca plc (AZN) first-quarter results, based on a poll of seven analysts conducted by Dow Jones Newswires (figures in million dollars, EPS and dividend in dollar, target price in pence, according to IFRS).]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[New Research Approach Tailors Drugs to Patients]]></title>
<link><![CDATA[http://www.foxbusiness.com/business-leaders/2013/04/22/medimmunes-jallal-sheds-light-on-new-health-care-methods/?]]></link>
<guid>http://www.foxbusiness.com/business-leaders/2013/04/22/medimmunes-jallal-sheds-light-on-new-health-care-methods/</guid>
<pubDate><![CDATA[Mon, 22 Apr 2013 15:42:59 EDT]]></pubDate>
<description><![CDATA[Transforming grief into drive to transform the medical world. MedImmune’s executive vice president Bahija Jallal leads the push to bring a new kind of science called translational medicine to biotech heavyweight AstraZeneca.]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/fb2/news/AZ-photo.jpg</media:thumbnail>
</item>
<item>
<title><![CDATA[Under The Hood: An ETF For International Income]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/18/under-hood-etf-for-international-income/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/18/under-hood-etf-for-international-income/</guid>
<pubDate><![CDATA[Thu, 18 Apr 2013 11:33:22 EDT]]></pubDate>
<description><![CDATA[This week has been kind to income investors looking for new ETFs to consider as Northern Trust's (NASDAQ:NTRS) FlexShares unit has rolled out three new global dividend funds.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[FDA Panel Backs Approval Of Glaxo, Theravance Lung Drug]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/17/fda-panel-backs-approval-glaxo-theravance-lung-drug/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/17/fda-panel-backs-approval-glaxo-theravance-lung-drug/</guid>
<pubDate><![CDATA[Wed, 17 Apr 2013 15:26:22 EDT]]></pubDate>
<description><![CDATA[A federal advisory panel said Wednesday a proposed lung drug from GlaxoSmithKline PLC (GSK, GSK.LN) was safe and effective at treating chronic obstructive pulmonary disease, or COPD, and recommended the product's approval.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[LONDON MARKETS: Miners Rebound In London; Pharma, Oil Firms Off]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/16/london-markets-miners-rebound-in-london-pharma-oil-firms-off/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/16/london-markets-miners-rebound-in-london-pharma-oil-firms-off/</guid>
<pubDate><![CDATA[Tue, 16 Apr 2013 12:27:34 EDT]]></pubDate>
<description><![CDATA[U.K.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[LONDON MARKETS: M&S Leads FTSE 100 To Fourth Day Of Gains]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/11/london-markets-ms-leads-ftse-100-to-fourth-day-gains/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/11/london-markets-ms-leads-ftse-100-to-fourth-day-gains/</guid>
<pubDate><![CDATA[Thu, 11 Apr 2013 12:27:34 EDT]]></pubDate>
<description><![CDATA[Shares of Marks & Spencer Group PLC led U.K.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Some Drug Makers Cut Payments, Meals Provided to Doctors]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/10/some-drug-makers-cut-payments-meals-provided-to-doctors/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/10/some-drug-makers-cut-payments-meals-provided-to-doctors/</guid>
<pubDate><![CDATA[Wed, 10 Apr 2013 15:39:41 EDT]]></pubDate>
<description><![CDATA[Two pharmaceutical companies that are among the biggest payers of fees to doctors reduced such spending last year by double-digit percentages, as greater transparency sheds light on the hundreds of millions of dollars the industry pays physicians for marketing and research efforts.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[AstraZeneca's new strategy gets thumbs down from S&P]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/08/astrazeneca-new-strategy-gets-thumbs-down-from-sp/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/08/astrazeneca-new-strategy-gets-thumbs-down-from-sp/</guid>
<pubDate><![CDATA[Mon, 08 Apr 2013 11:35:21 EDT]]></pubDate>
<description><![CDATA[Standard & Poor's cut its credit outlook for AstraZeneca to negative from stable on Monday in response to a major strategy update by the drugmaker's new chief executive last month.]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/fb2/feeds/Reuters/2013/04/08/2013-04-08T153521Z_1_CBRE93717B200_3_MCGRAWHILL-SANDP-CIVILCHARGES.JPG</media:thumbnail>
</item>
<item>
<title><![CDATA[AstraZeneca's Arthritis Pill Disappoints in Late-Stage Trial]]></title>
<link><![CDATA[http://www.foxbusiness.com/industries/2013/04/05/astrazenecas-arthritis-pill-fails-to-meet-one-end-goal-in-late-stage-trial/?]]></link>
<guid>http://www.foxbusiness.com/industries/2013/04/05/astrazenecas-arthritis-pill-fails-to-meet-one-end-goal-in-late-stage-trial/</guid>
<pubDate><![CDATA[Fri, 05 Apr 2013 10:40:11 EDT]]></pubDate>
<description><![CDATA[AstraZeneca’s rheumatoid arthritis pill fostamatinib failed to meet one of the end goals of a late-stage clinical trial, raising doubt in the pill and the drug company’s ability to revamp its battered pipeline.]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/fb2/news/AstraZeneca.jpg</media:thumbnail>
</item>
<item>
<title><![CDATA[AstraZeneca Reports Top-Line Phase III OSKIRA-1 Study of Fostamatinib]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/05/astrazeneca-reports-top-line-phase-iii-oskira-1-study-fostamatinib/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/05/astrazeneca-reports-top-line-phase-iii-oskira-1-study-fostamatinib/</guid>
<pubDate><![CDATA[Fri, 05 Apr 2013 02:24:52 EDT]]></pubDate>
<description><![CDATA[AstraZeneca PLC (AZN.LN), a global, innovation-driven biopharmaceutical business, said Friday top-line results of OSKIRA-1--a Phase III study to assess the efficacy and safety of fostamatinib--shows fostamatinib achieved a statistically significant improvement in ACR20 response rate at 24 weeks, but didn't demonstrate a statistically significant difference in mTSS compared with placebo.]]></description>
<media:thumbnail/>
</item>
</channel>
</rss>
